Monitoring brain tumor progression is a complex balancing act between objective imaging and subjective clinical changes. In a ...

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

In an interview on treatments following failure of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, Rahul ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Cabozantinib is presented as an emerging option with activity across extrapancreatic neuroendocrine tumors. Dr Lieu ...

At 125 mg palbociclib, two DLTs occurred (grade 3 anemia and grade 3 hypoxia), with no treatment-related deaths; one cerebral hemorrhage death was reported. The LITESPARK-024 trial showed a manageable ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab ...

This marks the first time a bispecific ADC has demonstrated a dual benefit in both PFS and OS within a phase 3 trial for TNBC ...

Gemcitabine-iDRS did not show superior bladder-intact event-free survival over chemoradiotherapy and there were no patient ...